An expanding role for immunotherapy is confirmed and a potential opportunity for VEGFR inhibition, and even future targets in fibroblast growth factor receptor (FGFR) and PI3K-AKT that collectively should improve survival as well as quality of life for those affected by squamous cell lung cancer over the next decade are confirmed.
This phase 2 multicenter study evaluated incorporation of autologous stem cell transplant (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma and met the primary endpoint, with an sCR rate of 60% after 8 cycles.
It is proposed that bendamustine, similar to the alkylating agent ifosfamide, is toxic to the glomerulus and proximal tubule cells and is the most likely cause of the patient's nephrogenic DI.
A GA-guided MDC for older HCT candidates is feasible and seems to reduce transplant-associated morbidity and mortality, and should encourage broader and safer utilization of transplantation in older patients.
A higher incidence of regional cancer and surgery and a lower incidence of the JAK2 V617F mutation are found in patients diagnosed with splanchnic vein thrombosis.
High baseline and progressive increases in NLRs are associated with progressive disease, inferior OS and weight loss in NSCLC patients, and these observations suggest that studying molecular mediators of cachexia/inflammation and their relationships to tumor progression may identify new therapeutic targets in the large subset of NSClC patients who have cancer cachexia.
Cognitive impairment elevates risk of post-alloHCT NRM in older patients, according to a preplanned subgroup analysis in 224 patients aged ≥60 years.
An international panel of MM investigators convenes to harmonize how MRD should be assessed and reported in MM clinical trials, and provides guidance regarding the incorporation of newer peripheral blood-based and imaging-based approaches to detection of residual disease.